Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + tofacitinib
- Development stage
- Unknown
- Lead developer
- Philippe ROUSSELOT
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Venetoclax + tofacitinib is an investigational drug combination being evaluated for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). Venetoclax is a small molecule inhibitor of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein often overexpressed in leukemic cells. Tofacitinib is a small molecule Janus kinase (JAK) inhibitor, specifically targeting JAK3 and JAK1, which inhibits the IL7R/JAK-STAT signaling pathway. This pathway is frequently dysregulated in T-ALL and contributes to cell survival and proliferation. The combination is being studied in precision medicine trials, such as the ALL-TARGET trial led by Philippe Rousselot, where patients are selected based on BCL2 expression and IL7R pathway status.
- Other names
- venetoclax and tofacitinibvenetoclax/tofacitinib
02
Targets
TYK2 (Tyrosine kinase 2)BCL-2 (BCL-2 family)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)JAK3 (Janus kinase 3)
Beyond the preview
Go deeper on venetoclax + tofacitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + tofacitinib.